# A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

> **NCT05357989** · PHASE3 · COMPLETED · sponsor: **Annovis Bio Inc.** · enrollment: 523 (actual)

## Conditions studied

- Parkinson's Disease, Idiopathic

## Interventions

- **DRUG:** buntanetap/posiphen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05357989
- **Lead sponsor:** Annovis Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-03
- **Primary completion:** 2023-12-04
- **Final completion:** 2023-12-04
- **Target enrollment:** 523 (ACTUAL)
- **Last updated:** 2025-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357989, "A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05357989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*